With top notch personnel, the factory, the cash injection, the promising early results, the interests from oncology practitioners, the FDA support and the recent job advertisement, you could be forgiven for thinking that IMU is looking more and more enticing as a 'turn key' solution for a BP looking to bolster their corporate assets and future by acquiring a whole owned subsidiary in oncology research and development, which can fit into their sales, marketing and distrbution infrastructure.
A mini Genetech or 'IMU 2.0' indeed!
dyor.
With top notch personnel, the factory, the cash injection, the...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.7¢ |
Change
0.001(1.79%) |
Mkt cap ! $418.9M | |||
| Open | High | Low | Value | Volume |
| 5.6¢ | 5.7¢ | 5.4¢ | $461.9K | 8.347M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 1082545 | 5.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 603058 | 6 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |